Open Access

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

  • Catherine S Adamson1, 3Email author,
  • Michael Sakalian2,
  • Karl Salzwedel2 and
  • Eric O Freed1
Retrovirology20107:36

https://doi.org/10.1186/1742-4690-7-36

Received: 12 January 2010

Accepted: 20 April 2010

Published: 20 April 2010

Abstract

Background

The maturation inhibitor bevirimat (BVM) potently inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking capsid-spacer peptide 1 (CA-SP1) cleavage. Recent clinical trials demonstrated that a significant proportion of HIV-1-infected patients do not respond to BVM. A patient's failure to respond correlated with baseline polymorphisms at SP1 residues 6-8.

Results

In this study, we demonstrate that varying levels of BVM resistance are associated with point mutations at these residues. BVM susceptibility was maintained by SP1-Q6A, -Q6H and -T8A mutations. However, an SP1-V7A mutation conferred high-level BVM resistance, and SP1-V7M and T8Δ mutations conferred intermediate levels of BVM resistance.

Conclusions

Future exploitation of the CA-SP1 cleavage site as an antiretroviral drug target will need to overcome the baseline variability in the SP1 region of Gag.

Background

Human immunodeficiency virus type 1 (HIV-1) infectivity is dependent on virion maturation, a morphological rearrangement of the viral core that occurs concomitant with virus particle release [1, 2]. HIV-1 maturation is triggered by cleavage of the Gag polyprotein, catalyzed by the viral protease (PR), into the matrix (MA), capsid (CA), spacer peptide 1 (SP1), nucleocapsid (NC), spacer peptide (SP2) and p6 constituents. Gag cleavage occurs as a sequential cascade of steps that is kinetically controlled by the differential rate of processing at each of the five cleavage sites in Gag [39]. First, Gag is cleaved into two fragments, MA-CA-SP1 and NC-SP2-p6. Next, the MA and p6 domains are released, and finally the CA and NC domains are liberated from the remaining CA-SP1 and NC-SP2 processing intermediates. Morphological rearrangement of the viral core is triggered by the release of the mature CA domain, which reassembles into a hexameric lattice to form a condensed conical core.

The small molecule 3-O-(3',3'-dimethylsuccinyl)-betulinic acid (DSB), also known as PA-457, MPC-4326, or bevirimat (BVM), potently inhibits HIV-1 replication by inhibiting a late step in the proteolytic processing cascade of Gag by specifically blocking the cleavage of SP1 from the C-terminus of CA [1012]. Inhibiting CA-SP1 cleavage results in the formation of aberrant, non-infectious particles that fail to undergo proper maturation [9, 10]. The novel mechanism of action of BVM led to its designation as the first in a new class of antiretroviral drugs known as maturation inhibitors [1, 13, 14].

The potent in vitro activity of BVM [10], together with promising pharmacological and safety profiles in animal models and phase I clinical trials [1518], led to clinical testing of BVM efficacy in HIV-1-infected patients. Initial phase II clinical trials reported statistically significant, dose-dependent viral load reductions in HIV-1-infected patients [19]. However, further studies showed that up to 50% of patients receiving BVM did not exhibit significant viral load reductions [20]. Optimal BVM plasma concentrations were observed in many of the non-responder patients, implying that virological parameters could be responsible for part of the observed variable clinical outcome [20]. Population genotyping of patient isolates demonstrated that the BVM-resistance mutations identified in in vitro selection studies were not present in the non-responding cohort [21]. The in vitro selected BVM-resistance mutations map to three highly conserved residues at the extreme C-terminus of CA (CA-H226Y, L231M and L231F) and the first and third residues of SP1 (SP1-A1V, A3V and A3T) [10, 11, 22]. Instead, the presence of baseline polymorphisms at SP1 residues 6-8 in the relatively non-conserved C-terminal portion of SP1 correlated with patients' failure to respond [20]. Patients infected with isolates encoding the clade B consensus amino acid sequence glutamine-valine-threonine (QVT) at these positions were significantly more likely to respond to BVM treatment than were patients infected with virus encoding polymorphisms at these positions [20].

A high-throughput in vitro phenotypic infectivity assay has been used to evaluate the correlation between a panel of naturally occurring Gag polymorphisms at SP1 residues 6-8 (SP1/6-8) and BVM susceptibility [23]. Specific polymorphisms at SP1 residues 7 and 8 (SP1-V7A, -V7M, -T8Δ and -T8N) were shown to be sufficient to confer decreased BVM susceptibility, while other mutations at SP1 residues 6 and 8 (SP1-Q6A, -Q6H and -T8A) retained sensitivity [23]. BVM susceptibility was reported as a fold change in IC50 value; the impact of these mutations on CA-SP1 processing or replication fitness was not reported.

Results and Discussion

Effect of SP1 mutations on CA-SP1 processing

To extend our understanding of the relationship between Gag polymorphisms at SP1/6-8 and BVM susceptibility, we employed a quantitative biochemical CA-SP1 processing assay that we have previously used to analyze in vitro-selected BVM-resistance mutations [22, 24]. Point mutations at SP1/6-8 were introduced into the infectious HIV-1 molecular clone pNL4-3 [25] to generate pNL4-3 SP1-Q6A, -Q6H, -V7A, -V7 M, -T8A and -T8Δ (Fig. 1A). This panel includes both alanine-scanning mutations across the residues of interest and several observed Gag polymorphisms (SP1-Q6H, -V7A, -V7 M, -T8A, and -T8Δ) [23, 26]. WT pNL4-3, which contains the QVT motif at SP1/6-8, was used as a BVM-susceptible virus and the previously characterized SP1-A1V mutant served as a prototypical BVM-resistant virus [10, 16, 22, 24]. The CA-SP1 processing assay was performed as previously described [22, 24, 27]. Briefly, HeLa cells transfected with WT or mutant pNL4-3 molecular clones were cultured either with no drug or with 1 μg/ml BVM. The cells were metabolically labeled with [35S]Met/Cys, and cell- and virion-associated proteins were immunoprecipitated with HIV-Ig. CA-SP1 cleavage was detected (Fig. 1B) and quantified as the percentage of CA-SP1 relative to total CA-SP1 plus CA (Fig. 1C). Consistent with our previous results, treatment of WT-transfected cells with BVM resulted in a marked accumulation of CA-SP1 in both cell and virion fractions. Similar levels of CA-SP1 were observed in the SP1-Q6A, -Q6H and -T8A BVM-treated samples. In contrast, CA-SP1 processing in SP1-V7A BVM-treated samples was similar to that seen in untreated WT or SP1-A1V samples. Interestingly, intermediate levels of CA-SP1 processing were observed in SP1-V7M and -T8Δ virions produced from BVM-treated cells. The result with SP1-T8Δ is consistent with previous analysis of this mutant [28]. The biochemical data obtained were also used to estimate virus release efficiency for each of the SP1 mutant derivatives in the absence and presence of BVM relative to untreated WT. Virus release efficiency was not significantly affected, with the exception of the SP1-V7A mutant cultured in the absence of drug, where a 3-fold reduction in virus release efficiency was observed (data not shown).
Figure 1

Mutagenesis at SP1 residues 6-8 results in varying degrees of CA-SP1 processing in the presence of BVM. (A) Mutagenesis of SP1 residues 6-8. HIV-1 Gag is represented at the top. The MA, CA, NC and p6 domains and the SP1 and SP2 spacer peptides are indicated. The alignment shows the pNL4-3 wild type (WT) amino acid sequence at the CA-SP1 junction in Gag and the panel of SP1 mutant derivatives examined in this study. The residues to which BVM resistance was previously mapped in vitro are shaded in grey. (B and C) Quantitative CA-SP1 processing assay. HeLa cells were transfected with WT pNL4-3 and the panel of SP1 mutant derivatives and cultured either without BVM or in 1 μg/ml BVM. Cells were metabolically labeled for 2 h with [35S]Met/Cys, and released virions were pelleted by ultracentrifugation. Cell and virus lysates were immunoprecipitated with HIV-Ig, and processing of CA-SP1 to CA was analyzed by SDS-PAGE and fluorography (B) and by phosphorimager analysis to quantify the percentage of CA-SP1 relative to total CA-SP1 plus CA (C). Error bars indicate standard deviations (n = 3-5).

Effect of SP1 mutations on sensitivity to BVM in a single-cycle infectivity assay

We next sought to examine the effect of the SP1/6-8 mutations on virus infectivity using a single-cycle infectivity assay in the TZM-bl indicator cell line [29, 30]. Virions produced from transfected HeLa cells cultured either without drug or with 1 μg/ml BVM were used to infect TZM-bl cells and luciferase activity was measured 48 hours postinfection (Fig. 2). The SP1/6-8 mutations did not significantly impact virus infectivity when particles were generated in the absence of BVM. However, virus infectivity was clearly inhibited when the WT, SP1-Q6A, -Q6H and -T8A viruses were generated in the presence of BVM. In contrast, BVM treatment did not reduce the ability of SP1-A1V or -V7A viruses to infect TZM-bl cells. Infectivity of viruses harboring the SP1-V7M and -T8Δ mutations was only moderately inhibited when produced in the presence of BVM.
Figure 2

Residue 6-8 mutations result in varying levels of resistance to BVM. (A) Virus stocks produced from HeLa cells either in the absence of BVM or in the presence of 1 μg/ml BVM were used to infect the TZM-bl indicator cell line. Infectivity was measured 48 h postinfection by determining levels of luciferase activity. Relative infectivity was calculated by normalization of the untreated WT virus at the 12.5 μl viral input to 100%. Paired t tests were performed to evaluate differences between means. Statistically significant differences between pairs of means are indicated (*** P = 0.0001, ** P = 0.001, * = 0.01). (B) Virus inputs were verified by confirming that virus stocks contained comparable RT activities. All data shown are means and standard deviations from three independent experiments, performed in duplicate.

Effect of SP1 mutations on sensitivity to BVM in the context of a spreading infection

The biochemical and single-cycle infectivity data presented above suggest that the SP1/6-8 mutations confer varying levels of BVM resistance without compromising virus infectivity. To confirm this result and determine the effects of these mutations on virus replication capacity, we evaluated virus replication kinetics in the Jurkat T cell line. Each construct was transfected into the Jurkat T-cell line, and the cells were cultured either without BVM or in the presence of a suboptimal (50 ng/ml) or inhibitory (1 μg/ml) drug concentration (Fig. 3). Virus replication was monitored by RT activity. The maintenance of existing and/or acquisition of additional mutations was determined by extracting genomic DNA from cells at the peak of RT activity, PCR amplification of the Gag and PR coding regions and DNA sequencing [22, 24, 27] (Fig. 3). WT virus was fully inhibited at 1 μg/ml BVM but developed BVM resistance after 47 days in the presence of 50 ng/ml BVM by acquisition of an SP1-V7A mutation. The SP1-V7A substitution has not been observed in previous in vitro BVM-resistance selection studies [10, 11, 22, 24]. In agreement with our previous studies, the SP1-A1V mutant was fully resistant to BVM as it replicated with WT kinetics independent of BVM concentration and did not acquire additional mutations. The SP1/6-8 mutations were maintained in all cultures in which detectable virus replication occurred. In the absence of BVM, the mutant viruses replicated with essentially WT kinetics and did not acquire additional amino acid substitutions, demonstrating that no significant fitness cost was associated with the SP1/6-8 mutations in the Jurkat cell system. The SP1-V7A mutation exhibited resistance to BVM as its replication was only moderately delayed with increasing BVM concentration and it replicated without acquiring additional mutations. At the 50 ng/ml BVM concentration, the SP1-V7M virus was capable of replicating, albeit with a significant delay, without acquiring additional amino acid substitutions. However, at the 1 μg/ml concentration, detectable replication was even further delayed and was accompanied by the acquisition of an SP1-A1T substitution (Fig. 3). Although the SP1-A1T change has not previously been reported in association with BVM resistance [10, 11, 22, 24], it maps to the same residue as the robust SP1-A1V BVM-resistance mutation. In a repeat experiment, the same pattern of replication and mutation acquisition was observed for the V7M mutant, except that at 1 μg/ml BVM a CA-V230I substitution and the previously characterized SP1-A3V mutation were detected when virus replication emerged after 29 days in culture (data not shown). The CA-V230I substitution has previously been reported to be acquired in the context of a CA-L231 MBVM-resistance mutation combined with a mutant PR when propagated in the presence of BVM [24]. Interestingly, the CA-V230I substitution occurs frequently in HIV-1 isolates [26, 31, 32] and therefore could represent an additional Gag polymorphism associated with BVM resistance. Replication of SP1-T8Δ was significantly delayed at the 50 ng/ml BVM concentration and was only detected upon acquisition of the SP1-A1V BVM-resistance mutation (Fig. 3). No detectable replication was observed for the SP1-T8Δ virus at 1 μg/ml BVM for up to 53 days in culture. However, in a repeat experiment, replication emerged after 68 days in culture and was accompanied by acquisition of the SP1-A3V mutation (data not shown). No replication was detectable for the SP1-Q6A and -Q6H mutants in the presence of either 50 ng/ml or 1 μg/ml BVM. The SP1-T8A virus did not replicate at 50 ng/ml BVM; however, replication of this mutant was detected at 1 μg/ml BVM at day 45 posttransfection and was accompanied by acquisition of the SP1-A3V mutation (Fig. 3).
Figure 3

Replication kinetics of viruses containing mutations in SP1 residues 6-8. Jurkat T cells were transfected with WT pNL4-3 and the panel of SP1 mutant derivatives and cultured either without BVM or in 50 ng/ml or 1 μg/ml BVM. Cells were split every 2 days, and supernatants were reserved at each time point for RT analysis. All originally introduced mutations were maintained. The grey boxes indicate those cultures in which an additional mutation is acquired; both the introduced and the acquired mutations are indicated. The results shown are representative of at least 2 independent experiments. Results from the repeat experiment are described in the text.

Conclusions

The data presented here demonstrate that point mutations corresponding to commonly observed polymorphisms at SP1 residues 6-8 in HIV-1 clinical isolates confer varying degrees of susceptibility to BVM in the NL4-3 background. The SP1-Q6A, Q6H, and T8A mutants retained complete sensitivity to BVM. Mutations SP1-V7M and T8Δ exhibited an intermediate level of BVM susceptibility. The SP1-V7M mutant appeared less susceptible to BVM than did SP1-T8Δ; SP1-V7M BVM-treated virions accumulated less unprocessed CA-SP1 and the SP1-V7M virus replicated without acquisition of additional mutations at 50 ng/ml BVM, whereas robust SP1-T8Δ replication required acquisition of a previously characterized BVM-resistance mutation. The SP1-V7A mutant displayed full resistance to BVM in terms of CA-SP1 processing, single-cycle infectivity, and virus replication assays, and its resistance was comparable to that of the robust and frequently observed BVM-resistance mutant SP1-A1V.

The observed variability in BVM susceptibility conferred by different mutations at SP1 residues T8 and V7 is likely due to differential effects on the putative BVM binding pocket at the CA-SP1 junction of Gag. For example, deletion of residue 8 is a more substantial change than a T-to-A substitution and could therefore be predicted to have a greater effect on BVM's ability to bind Gag and exert its antiviral affect. Hence the T8Δ mutant exhibits intermediate resistance to BVM while T8A retains BVM susceptibility. Although binding of BVM to the CA-SP1 junction has previously been suggested by biochemical studies that examined other BVM-resistant mutants [33, 34], the lack of high-resolution structural information on this region of Gag hinders further elucidation at this time.

The data obtained in this study are in close agreement with the previously reported high-throughput phenotypic assay used to evaluate the association between Gag polymorphisms at SP1/6-8 and BVM susceptibility [23]. However, we extend the prior findings by evaluating the effects of SP1/6-8 mutations on CA-SP1 processing in the presence and absence of BVM, measuring the effects of these mutations on viral replication capacity, and performing BVM selections analyses with these mutants. In conclusion, baseline polymorphisms in the non-conserved C-terminal portion of SP1 represent a considerable challenge to the clinical development of BVM. In particular, the SP1-V7A polymorphism constitutes a significant obstacle as it displayed robust BVM-resistance in in vitro assays and has been shown to occur at high frequency in some HIV-1 subtypes [23]. Future exploitation of the CA-SP1 cleavage site as a molecular target for antiretroviral drug development will need to account for the baseline amino acid variability in this region of Gag.

Methods

BVM and cell culture

BVM was prepared as described previously [35] and used at the concentrations indicated. HeLa cells were maintained in Dulbecco Modified Eagle Medium (DMEM) supplemented with 5% (vol/vol) fetal bovine serum (FBS). TZM-bl indicator cells [obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID; [[29, 30]] were maintained in DMEM supplemented with 10% (vol/vol) FBS. The Jurkat T-cell line was maintained in RPMI-1640 supplemented with 10% (vol/vol) FBS. All media were supplemented with L-glutamine (2 mM), penicillin and streptomycin.

Generation of SP1 mutants and transfections

Point mutations at SP1 residues 6-8 (SP1/6-8) were introduced into the infectious HIV-1 molecular clone pNL4-3 [25] by using site-directed mutagenesis to generate pNL4-3 SP1-Q6A, Q6H, V7A, V7 M, T8A and T8Δ (Fig. 1A). Plasmid DNA was purified with the plasmid purification maxiprep kit (QIAGEN), adjusted to 1 μg/μl and the identities of all plasmids were confirmed by DNA sequencing. HeLa cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Jurkat T cells were transfected by using DEAE-dextran [36].

Radioimmunoprecipitation analysis

Methods used for metabolic labeling of HeLa cells, preparation of cell and virus lysates, and immunoprecipitation have been previously described in detail [22, 27, 37]. Briefly, media and solutions containing BVM at the indicated concentrations were prepared immediately before use and mixed by vortexing. BVM was maintained throughout the transfection and radioimmunoprecipitation procedures. HeLa cells were transfected with wild-type (WT) or the SP1 mutant derivative pNL4-3 clones. Transfected HeLa cells were starved in Cys/Met-free medium for 30 min and then metabolically radiolabeled for 2 h with [35S]Cys/Met Pro-mix (Amersham). Virions were pelleted by ultracentrifugation. Cell and virus lysates were immunoprecipitated with pooled immunoglobulin from HIV-1-infected patients (HIV-Ig) obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID. The radioimmunoprecipitated proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and exposed to X-ray film and a phosphorimager plate (Fuji) and the bands were quantified by using Quantity One software (Bio-Rad).

Single-cycle infectivity assay

Virus stocks of were produced by transfecting HeLa cells with WT and SP1 mutant pNL4-3 derivatives and then cultured either without BVM or with 1 μg/ml BVM. Twenty-four hours posttransfection, the cells were washed twice and fresh medium containing either no BVM or 1 μg/ml BVM was added. Following a 4-hour incubation, virus-containing supernatant was collected, filtered and used to infect TZM-bl cells. Infections were carried out for 2 hours in the presence of 10 μg/ml DEAE-dextran. The cells were then washed, cultured without BVM, and luciferase activity measured 48 hours postinfection using the luciferase assay system (Promega). Reverse transcriptase (RT) activities in the virus stocks were measured as previously described [27].

Replication kinetics

Jurkat T cells were transfected with pNL4-3 WT and SP1 mutant derivatives. BVM was added at the time of transfection at the indicated concentrations and was maintained throughout the course of the experiment. The Jurkat cells were split every two days, supernatant collected at each time point and viral replication monitored by RT activity as previously described [27]. Cell pellets and virus supernatants were harvested on the days of peak RT activity. To verify that the SP1 mutations were maintained and to investigate acquisition of additional mutations, genomic DNA was extracted from cells on the day of peak RT activity using a whole-blood DNA extraction kit (QIAGEN). The entire Gag-PR coding region was then amplified by PCR by using the forward and reverse primers NL516F (5'-TGC CCG TCT GTT GTG TGA CTC-3') and NL2897R (5'-AAA ATA TGC ATC GCC CAC AT-3') respectively. The resultant 2.3 kb PCR product was purified by using the QIAquick PCR purification kit (QIAGEN) and sequenced using the primers NL1410F (5'-GGA AGC TGC AGA ATG GGA TA-3'), NL1754F (5'-TGG TCC AAA ATG CGA ACC-3') and NL2135F (5'-TTC AGA GCA GAC CAG AGC CAA-3') [22, 24].

Declarations

Acknowledgements

We thank members of the Freed laboratory for helpful discussions and critical review of the manuscript. We acknowledge the NIH AIDS Reagent Program for providing HIV-Ig and TZM-bl cells. This research was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH and by the Intramural AIDS Targeted Antiviral Program.

Authors’ Affiliations

(1)
Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute
(2)
Panacos Pharmaceuticals Inc
(3)
Bute Medical School, University of St Andrews, Westburn Lane

References

  1. Adamson CS, Salzwedel K, Freed EO: Virus maturation as a new HIV-1 therapeutic target. Expert Opin Ther Targets. 2009, 13: 895-908. 10.1517/14728220903039714.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Ganser-Pornillos BK, Yeager M, Sundquist WI: The structural biology of HIV assembly. Curr Opin Struct Biol. 2008, 18: 203-217. 10.1016/j.sbi.2008.02.001.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Vogt VM: Proteolytic processing and particle maturation. Curr Top Microbiol Immunol. 1996, 214: 95-131.PubMedGoogle Scholar
  4. Krausslich HG, Schneider H, Zybarth G, Carter CA, Wimmer E: Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J Virol. 1988, 62: 4393-4397.PubMed CentralPubMedGoogle Scholar
  5. Mervis RJ, Ahmad N, Lillehoj EP, Raum MG, Salazar FH, Chan HW, Venkatesan S: The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors. J Virol. 1988, 62: 3993-4002.PubMed CentralPubMedGoogle Scholar
  6. Erickson-Viitanen S, Manfredi J, Viitanen P, Tribe DE, Tritch R, Hutchison CA, Loeb DD, Swanstrom R: Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses. 1989, 5: 577-591. 10.1089/aid.1989.5.577.View ArticlePubMedGoogle Scholar
  7. Tritch RJ, Cheng YE, Yin FH, Erickson-Viitanen S: Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol. 1991, 65: 922-930.PubMed CentralPubMedGoogle Scholar
  8. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, Swanstrom R: The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol. 1994, 68: 8017-8027.PubMed CentralPubMedGoogle Scholar
  9. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG: Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol. 1998, 72: 2846-2854.PubMed CentralPubMedGoogle Scholar
  10. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT: PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA. 2003, 100: 13555-13560. 10.1073/pnas.2234683100.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, Aiken C, Chen CH: Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol. 2004, 78: 922-929. 10.1128/JVI.78.2.922-929.2004.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Zhou J, Chen CH, Aiken C: The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. Retrovirology. 2004, 1: 15-10.1186/1742-4690-1-15.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Aiken C, Chen CH: Betulinic acid derivatives as HIV-1 antivirals. Trends Mol Med. 2005, 11: 31-36. 10.1016/j.molmed.2004.11.001.View ArticlePubMedGoogle Scholar
  14. Salzwedel K, Martin DE, Sakalian M: Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007, 9: 162-172.PubMedGoogle Scholar
  15. Martin DE, Salzwedel K, Allaway GP: Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008, 19: 107-113.View ArticlePubMedGoogle Scholar
  16. Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE: Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS ONE. 2007, 2: e1251-10.1371/journal.pone.0001251.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Martin DE, Blum R, Doto J, Galbraith H, Ballow C: Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet. 2007, 46: 589-598. 10.2165/00003088-200746070-00004.View ArticlePubMedGoogle Scholar
  18. Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, Smith PC, Ballow C: Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother. 2007, 51: 3063-3066. 10.1128/AAC.01391-06.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE: Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007, 51: 3574-3581. 10.1128/AAC.00152-07.PubMed CentralView ArticlePubMedGoogle Scholar
  20. McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, Martin D, Salzwedel K, Allaway G: HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir Ther. 2008, 13: A10-Google Scholar
  21. Castillo A, Adamson C, Doto J, Yunus A, Wild C, Martin D, Allaway G, Freed E, Salzwedel K: Genotypic analysis of the Gag-SP1 cleavage site in patients receiving the maturation inhibtor PA-457. Antivir Ther. 2006, 11: S37-Google Scholar
  22. Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO: In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol. 2006, 80: 10957-10971. 10.1128/JVI.01369-06.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ: Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother. 2009, 53: 2185-2188. 10.1128/AAC.01650-08.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO: Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol. 2009, 83: 4884-4894. 10.1128/JVI.02659-08.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986, 59: 284-291.PubMed CentralPubMedGoogle Scholar
  26. Kuiken C, Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Wolinsky S, Korber B: HIV Sequence Compendium 2009. 2009, Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico, LA-UR 09-03280Google Scholar
  27. Freed EO, Martin MA: Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol. 1994, 68: 2503-2512.PubMed CentralPubMedGoogle Scholar
  28. Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT: Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology. 2006, 356: 217-224. 10.1016/j.virol.2006.07.023.View ArticlePubMedGoogle Scholar
  29. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998, 72: 2855-2864.PubMed CentralPubMedGoogle Scholar
  30. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002, 46: 1896-1905. 10.1128/AAC.46.6.1896-1905.2002.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Malet I, Wirden M, Derache A, Simon A, Katlama C, Calvez V, Marcelin AG: Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. Aids. 2007, 21: 871-873. 10.1097/QAD.0b013e3280b079d9.View ArticlePubMedGoogle Scholar
  32. Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, Simon A, Katlama C, Costagliola D, Calvez V, Marcelin AG: Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect. 2007, 54: 367-374. 10.1016/j.jinf.2006.06.012.View ArticlePubMedGoogle Scholar
  33. Zhou J, Chen CH, Aiken C: Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol. 2006, 80: 12095-12101. 10.1128/JVI.01626-06.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Zhou J, Huang L, Hachey DL, Chen CH, Aiken C: Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem. 2005, 280: 42149-42155. 10.1074/jbc.M508951200.View ArticlePubMedGoogle Scholar
  35. Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB, Janzen WP, Chen IS, Lee KH: Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod. 1994, 57: 243-247. 10.1021/np50104a008.View ArticlePubMedGoogle Scholar
  36. Kiernan RE, Ono A, Englund G, Freed EO: Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol. 1998, 72: 4116-4126.PubMed CentralPubMedGoogle Scholar
  37. Willey RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD: Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci USA. 1988, 85: 9580-9584. 10.1073/pnas.85.24.9580.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Adamson et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.